Drug intelligence / Profile preview

MS-028

Development stage: Unknown
Lead developer: Mabscale

Overview

MS-028 is an investigational drug candidate currently in development by the Russian biotechnology company Mabscale, a subsidiary of Ozon Pharmaceuticals. While Mabscale specializes in the development of biosimilars and recombinant monoclonal antibodies for oncology and autoimmune diseases, specific details regarding the molecular target, mechanism of action, and primary therapeutic indications of MS-028 have not been publicly disclosed.

Beyond the preview

Go deeper on MS-028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MS-028.

Explore the full profile